AVAS-induced inhibition of peripheral cholesterol esterification was originally a therapeutic target for atherosclerosis as it facilitated cholesterol efflux to apoA1-HDL in plasma, thus reducing the development of foam cells from macrophage uptake of oxidized LDL. This evidence concerns the gene APOA1 and atherosclerosis.